Ex-Vyera exec describes strategy to prevent competition
Vyera Pharmaceuticals purchased the parasite-fighting drug Daraprim with the intention of foreclosing generic competition, a former executive has said.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10